A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

• Status: Terminated
• Trial end date: 2020-06-29
• Target enrollment: 0
• Participant gender: All

Summary

The endothelin receptor antagonist macitentan showed significant improvement compared with placebo in pulmonary vascular resistance (PVR) and 6-minute walking distance (6MWD) in inoperable CTEPH patients in the phase II MERIT-1 trial (AC-055E201, NCT02021292). However, in the MERIT-1 trial Japanese patients were not included. Therefore, in line with Japan's medical environment, this phase III study is to confirm the efficacy and safety of macitentan in Japanese CTEPH patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Actelion
• Collaborators: EPS Corporation; General Laboratory, BML, Inc.; Imepro Inc.; Mitsubishi Logistics Corporation
• Treatments: Macitentan

Criteria

Inclusion Criteria:

• Written informed consent to participate in the study obtained from the subject or legal representative a) prior to initiation of any study mandated procedure

• Japanese subjects who have been diagnosed as having CTEPH:

1. Subjects who have not undergone balloon pulmonary angioplasty (BPA) and for whom the investigator determines not to implement pulmonary endarterectomy (PEA) at the time of the acquisition of informed consent due to the organized thrombosis localized in the peripheral regions, high risk (complications, old age, etc.) or for any other reasons.

2. Subjects who have postoperative persistent or recurrent pulmonary hypertension (PH) after undergoing pulmonary endarterectomy (PEA) and/or BPA.

• PH subjects whose WHO FC is I to IV

• 6MWD measured during the screening period ranges from 150 m to 450 m

• Subjects who meet the following conditions according to the right heart catheterization (RHC) performed during the screening period or within 8 weeks before the acquisition of the informed consent:

1. Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg

2. Pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg (if PAWP cannot be measured or the value of PAWP is not reliable, left ventricular end-diastolic pressure ≤ 13 mmHg)

3. Resting PVR ≥ 400 dyn*sec/cm5

• Subjects treated with anti-coagulation agents, unfractionated heparin or low molecular weight heparin at least 90 days prior to RHC at baseline

• Women with childbearing potential with negative serum pregnancy test results and able to follow the appropriate contraceptive methods from the date of starting the study drug administration up to 30 days after the discontinuation or completion of the study drug administration. Fertile male subjects able to use condom during the same period.

Exclusion Criteria:

• BPA within 90 days prior to undergoing baseline RHC

• PEA within 180 days prior to undergoing baseline RHC

• Subjects with unstable pulmonary hemodynamics who have postoperative persistent or recurrent PH after undergoing PEA and/or BPA

• Recurrent thromboembolism undergoing treatment with oral anti-coagulation agents

• Symptomatic acute pulmonary embolism within 180 days prior to the start of study drug administration

• Known moderate-to-severe restrictive lung disease or obstructive lung disease or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema)

• Acute myocardial infarction during Screening period

• Severe liver impairment.

• Systolic blood pressure (SBP) < 90 mmHg at screening.

• Any known factor or disease that may interfere with treatment compliance or full participation in the study